Tyrosine Kinase/Adaptors
Tyrosine kinase and adaptor inhibitors are compounds that target tyrosine kinases and their associated adaptor proteins, which play pivotal roles in cell signaling, growth, and differentiation. These inhibitors are essential tools in cancer research, as many tyrosine kinases are involved in the signaling pathways that drive tumor growth and metastasis. By inhibiting tyrosine kinases, these compounds can block critical signaling cascades, offering potential therapeutic strategies for various cancers and other diseases involving abnormal cell signaling. At CymitQuimica, we provide a comprehensive range of high-quality tyrosine kinase and adaptor inhibitors to support your research in oncology, molecular biology, and targeted therapy development.
Subcategories of "Tyrosine Kinase/Adaptors"
- ALK(112 products)
- CSF-1R(42 products)
- EGFR(572 products)
- Ephrin Receptor(23 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(169 products)
- HER(5 products)
- Hck(3 products)
- IGF-1R(88 products)
- PDGFR(126 products)
- PYK2(7 products)
- Src(79 products)
- TAM Receptor(32 products)
- Tie-2(20 products)
- Trk receptor(59 products)
- Tyrosine Kinases(26 products)
- VEGFR(268 products)
- c-Fms(108 products)
- c-Kit(101 products)
- c-Met/HGFR(128 products)
- c-RET(51 products)
Show 13 more subcategories
Found 1370 products of "Tyrosine Kinase/Adaptors"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Valanafusp alfa
CAS:<p>Valanafusp alfa (AGT-181) is a fusion protein targeting HIR and IDUA for MPS I research.</p>Color and Shape:LiquidMecbotamab vedotin
CAS:<p>Mecbotamab vedotin (BA301) is an inhibitory IgG1 antibody that targets human tyrosine kinase receptor AXL and the humanized murine monoclonal BA301 γ1 chain. It can be utilized in the preparation of immunoconjugates for research into cancers expressing the Axl type.</p>Color and Shape:LiquidEGFR-IN-124
<p>EGFR-IN-124 (compound 10A) is an EGFR inhibitor with an IC50 value of 0.54 μM, utilized in cancer research.</p>Color and Shape:Odour SolidEGFR-IN-116
EGFR-IN-116 (compound 14D) is an antineoplastic agent. It exhibits an IC50 value of 0.103 μM for EGFR, 0.069 μM for VEGFR-2, and 19.74 μM for Topo II.Formula:C26H22N6O2SMolecular weight:482.1525GNF2133
CAS:<p>GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.</p>Formula:C24H30N6O2Purity:98.51%Color and Shape:SolidMolecular weight:434.53EGFR-IN-95
<p>EGFR-IN-95 is a derivative of 2,4-diaminonicotinamide. It effectively inhibits the activity of EGFRdel19/T790M/C797S and L858R/T790M/C797S.</p>Formula:C23H28F2N8O3SMolecular weight:534.19731Compound TPX-0046
CAS:<p>Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.</p>Formula:C21H21FN6O3Purity:99.94%Color and Shape:SoildMolecular weight:424.43Depatuxizumab MMAF
<p>Depatuxizumab-MMAF, an antibody-drug conjugate (ADC), comprises an EGFR-targeted antibody linked to McMMAF and is utilized in glioblastoma research.</p>Color and Shape:LiquidMolecular weight:148.24 kDaBTK inhibitor 17
CAS:<p>BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.</p>Formula:C25H24N6O3Purity:99.57% - 99.88%Color and Shape:SolidMolecular weight:456.5Lumretuzumab
CAS:<p>Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity.</p>Purity:95.3% (SDS-PAGE); 96.4% (SEC-HPLC) - 95.3% (SDS-PAGE); 96.4% (SEC-HPLC)Color and Shape:LiquidWAY-270250
CAS:<p>WAY-270250 is an IGF-1R/SRC inhibitor.</p>Formula:C18H16N2O2Purity:99.77%Color and Shape:SoildMolecular weight:292.33EGFR/HER2-IN-15
<p>EGFR/HER2-IN-15 is a dihydropyrimidine and an effective inhibitor of EGFR/HER2. It significantly suppresses EGFRwt activity with an IC50 of 37.21 nM and exhibits anticancer properties.</p>Formula:C28H29N3O6Molecular weight:503.20564EGFR-IN-43
<p>EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.</p>Formula:C50H55ClFN5O5Color and Shape:SolidMolecular weight:860.45Duligotuzumab
CAS:<p>Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.</p>Purity:95% - 95%Color and Shape:LiquidTimigutuzumab
CAS:<p>Timigutuzumab (GEXMab73) is a humanized monoclonal antibody designed to target ErbB2, showing potential application in cancer research [1].</p>Color and Shape:LiquidEGFR-IN-136
<p>EGFR-IN-136 (compound 21v) is a potent inhibitor of EGFR, demonstrating IC50 values of 20.2 nM, 1.2 nM, 2.3 nM, and 12.5 nM for EGFRWT, EGFRLR/TM, EGFR19D/TM/CS, and EGFRLR/TM/CS, respectively. It exhibits antiproliferative and antitumor activities and holds potential for research in non-small cell lung cancer (NSCLC).</p>Formula:C30H36N7O4PColor and Shape:SolidMolecular weight:589.625HER2/neu (654-662) GP2 acetate
<p>GP2 acetate, from HER2 (654-662), triggers HLA-A2-restricted T cells to attack epithelial cancers.</p>Formula:C44H81N9O13Purity:98%Color and Shape:SolidMolecular weight:944.17Enapotamab vedotin
CAS:<p>Enapotamab vedotin (anti-AXL ADC) targets AXL with MMAE payload, showing potential against AXL-expressing, EGFR-resistant NSCLC.</p>Purity:95%Color and Shape:LiquidEGFR-IN-148
<p>EGFR-IN-148 (compound 8c) is a potent EGFR inhibitor with an IC50 of 0.161 μM. It induces G1/S phase arrest and significantly enhances apoptosis in HepG2 cells.</p>Formula:C17H16N4O4SColor and Shape:SolidMolecular weight:372.398Hck-IN-2
<p>Hck-IN-2 (Compound 8e) acts as an HCK inhibitor with demonstrated cytotoxic effects on tumor cells. It exhibits an IC50 of 19.58 μM for MDA-MB231 cells and 1.42 μM for MCF-7 cells. Additionally, Hck-IN-2 possesses antitumor activity.</p>Formula:C36H35FN6O10Color and Shape:SolidMolecular weight:730.696
